logo

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

European News

Plant Expansion: Daiichi Sankyo Inaugurates New Building for Pharmaceutical Development in Pfaffenhofen, Bavaria

Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA® (edoxaban) in Japan

PREFER in VTE registry reveals new insights into use of Novel Oral Anticoagulants (NOACs) in the treatment and management of venous thromboembolism (VTE)

One year data from the PREFER in AF registry show significant changes in atrial fibrillation (AF) management in Europe and implementation of clinical guidelines

Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes

Global Survey of Cardiologists Highlights Complexity of Managing Non-Valvular Atrial Fibrillation and Reinforces Need for Individualized Approach to Patient Care

ESC Congress 2014: Make Your Heart Feel Good!

World Hypertension Day 2014

Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion

Once-Daily Edoxaban Evaluated in Two Subgroup Analyses of East Asian Patients from the Largest Comparative Phase 3 Trials of a Novel Oral Anticoagulant